<DOC>
	<DOCNO>NCT02137928</DOCNO>
	<brief_summary>This study evaluate clinical efficacy periocular injection carboplatin together chemotherapy treatment Retinoblastoma compare chemotherapy alone .</brief_summary>
	<brief_title>Carboplatin Periocular Injection Retinoblastoma</brief_title>
	<detailed_description>This study phase Ⅲ open label interventional case series . Patients retinoblastoma randomize receive chemotherapy without periocular injection carboplatin dose 20mg/2 ml . Patients receive carboplatin periocular monthly basis total duration therapy 6 month . Patients follow 24 month .</detailed_description>
	<mesh_term>Retinoblastoma</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<criteria>Ability provide write informed consent comply study assessment full duration study . linical diagnosis retinoblastoma , Stage 0 Ⅱ base International Retinoblastoma Staging System . Any previous disease study eye . Previous participation study investigational drug within 1 month precede Day 0 ( exclude vitamin mineral ) . History chemical intervention retinoblastoma study eye .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>Retinoblastoma</keyword>
	<keyword>carboplatin</keyword>
</DOC>